Search

BACKGROUND Botulinum toxin type A (BoNTA) is standard of care for glabellar lines ameliorization. DaxibotulinumtoxinA for Injection (DAXI) is a new BoNTA with a unique formulation representing the latest advancement in BoNTA technology. There is an unmet need for patients to understand the full potential of BoNTA treatment and new technologies. OBJECTIVE To update clinical data supporting the use of DAXI for glabellar lines within the context of clinical experience. MATERIALS AND METHODS A narrative review of the literature and summary of clinical experience with DAXI. RESULTS The DAXI clinical trial program reflects clinical experience post-FDA approval, with DAXI demonstrating rapid onset, high patient response rates, and extended treatment duration versus conventional BoNTAs. Clinical observations suggest that DAXI has limited diffusion from the injection site, enabling more localized control of muscle activity and greater improvements in wrinkle severity. DAXI enables practitioners to exert greater finesse in their injections and in predicting changes to eyebrow shape and position and achieve improvement in skin quality. CONCLUSION Advances in BoNTA technology can provide patients with greater options for treatment outcomes. The potential for enhanced localized effects with DAXI may contribute to more precise and targeted effects on muscle activity and additional aesthetic benefits to patients. [ABSTRACT FROM AUTHOR]

Introduction: Real‐world experience using an allograft adipose matrix (AAM) (Renuva) is presented as a series of seven cases demonstrating successful use of the matrix by nine expert cosmetic physicians across the United States. AAM is donated tissue that is aseptically processed without terminal irradiation into a transplantable adipose matrix that functions as a natural, versatile, and nonimmunogenic cushioning and volume‐restoring tissue. When injected, the adipose matrix is replaced with the body's own fat cells and provides the cellular scaffold required for volume restoration and retention. Methods: Nine expert dermatologists were selected to share and discuss real‐world patient cases using AAM. The experts discussed a variety of cases and selected 7 cases that demonstrated successful, novel use of AAM to present in this manuscript. Results: Experts agreed that the novel AAM is an easy‐to‐use, effective, and safe alternative to traditional fillers and fat grafting. Conclusion: The use of the AAM is recommended for the face, hands, and other adipose tissue‐containing parts of the body. The presented real‐world cases provide guidance on how to identify ideal candidates to ensure optimal volume restoration results. [ABSTRACT FROM AUTHOR]

Background Tapencarium (RZL-012) (5-(3.6-dibromo-9H-carbazol-9-yl)-N, N, N-trimethylpentan-1-aminium chloride) is a novel injectable synthetic molecule with cytolytic properties, capable of reducing subcutaneous fat volume. Objectives The goal of this 3-armed, randomized, double-blind, placebo-controlled phase 2b study was to determine the safety and efficacy of low- and high-dose RZL-012 vs placebo on submental fat (SMF) reduction. Methods Patients (n = 151, age 18-65 years) with excess SMF received a single treatment session of RZL-012 or placebo in the submental area, after which they were monitored for 84 days. SMF was assessed at baseline and after dosing with newly developed scales, namely the Clinician Chin Assessment Tool (C-CAT) and Subject Chin Assessment Tool (S-CAT). SMF was also assessed by magnetic resonance imaging (MRI) at screening and on Day 84 after treatment. Results The proportion of patients who had a 1-grade or 2-grade improvement in C-CAT and/or S-CAT on Day 84 vs baseline was significantly higher in the high-dose RZL-012 group vs the placebo group (P <.002). The relative percentage reduction in MRI-measured SMF volume (Day 84 vs screening) was significantly greater in the high-dose RZL-012 group vs the low-dose RZL-012 or the placebo group (P <.0001). Local injection site reactions were the most common adverse events (AEs). Conclusions A single administration of RZL-012 into SMF resulted in significant improvement in submental appearance as assessed by clinicians, patients, and MRI. From a safety perspective, there were no serious AEs and no clinically significant changes in vital signs or laboratory tests over the course of the study. Level of Evidence: 1 [ABSTRACT FROM AUTHOR]

Background: Since 1936, injectable carboxytherapy has been used for the treatment of circulatory issues and lack of tissue trophism. In the last 25 years, it has been applied to aesthetic issues, especially those related to the signs and symptoms of skin aging. Presently, carboxytherapy is available as a combination of transcutaneous gels that produce CO2 with benefit for atrophic skin. Objective: The objective of this study was to investigate the efficacy and safety of a topical carboxy mask on facial photoaging after short term use of 4 weeks and long term use of 10 weeks. Methods: The short term study was conducted for 14 days after 3 times weekly application of the facial mask for 1 h followed by a regression phase with evaluations at days 21 and 28. 11 healthy female subjects age 45–75 years were enrolled. Subjects applied the facial mask for 45 min, 3 times per week during the 2‐week treatment period. The long term study was conducted for 10 weeks on 35 subjects 35–65 years with mild to moderate facial photoaging of Fitzpatrick skin types I–VI. Subjects underwent photography, elasticity, hydration, and VAS questionnaire assessments. Results: The short term 4 week study demonstrated improvement in laser‐Doppler measured blood flow and skin hydration. The long term 10 week study demonstrated improvement in firmness (16%, p = 0.001), sagging (9%, p = 0.023), and overall skin appearance (12%, p = 0.002). These findings were supported by the retraction time decrease at week 10 (−10%, p = 0.05). Summary: The combination of two gels produced the liberation of CO2, which improved short term skin hydration after 4 weeks of use and improved longer term skin elasticity after 10 weeks of use. [ABSTRACT FROM AUTHOR]

Abstract Objective: Treatment of acne vulgaris with light sources necessitates multiple targets including Propionibacterium acnes and sebaceous glands. Traditional light sources such as blue light capitalize on P acnes bacteria [...]

Background: A global approach to facial rejuvenation involves multiple treatment modalities.Objectives: The aim of this study was to evaluate the impact of multimodal facial aesthetic treatment on self-reported psychological and social outcomes.Methods: HARMONY, a prospective, multicenter, 4-month study, enrolled patients aged 35 to 65 years to receive on-label treatment with a combination of hyaluronic fillers (VYC-20L, HYC-24L, and/or HYC-24L+), onabotulinumtoxinA, and bimatoprost. Fillers were injected on Day 1, with touch-ups performed on Day 14. OnabotulinumtoxinA was injected at Month 3 into glabellar lines and/or crow's feet lines. Patients applied bimatoprost to eyelashes once daily for 17 weeks. Mean change from baseline on FACE-Q Psychological Well-being and Social Confidence Scales, FACE-Q Aging Appearance Appraisal Scale, and FACE-Q Age Appraisal Visual Analog Scale were assessed.Results: Of 100 patients treated, 93 were evaluated at 4 months posttreatment. Significant improvement vs baseline was observed on the FACE-Q Scales for Psychological Well-being (mean change, -19.9; P < 0.00001), Social Confidence (mean change, -18.2; P < 0.00001), and Aging Appearance (mean change, -28.5; P < 0.0001). On average, patients' self-assessed age was 0.1 years older than actual age at baseline and 4.5 years younger at Month 4 (P < 0.001 vs baseline). Forty-two patients experienced adverse events, all mild to moderate.Conclusions: Multimodal, full facial aesthetic treatment improves patients' self-reported psychological well-being, social confidence, aging appearance, and perceptions of chronologic age.Level Of Evidence:4: [ABSTRACT FROM AUTHOR]